The Library
The SSTARS (STeroids and Stents Against Re-Stenosis) Trial : different stent alloys and the use of peri-procedural oral corticosteroids to prevent in-segment restenosis after percutaneous coronary intervention
Tools
Adam, Z., Turley, Andrew, Mason, James, Kasim, A. S., Newby, David E., Mills, N., Padfield, G., Thompson, L., Morley, R., Hall, J. A., Wright, R. A., Muir, D. F., Sutton, A. G. C., Swanson, N., Carter, J., Bilous, R., Jones, S. and de Belder, M. A. (2016) The SSTARS (STeroids and Stents Against Re-Stenosis) Trial : different stent alloys and the use of peri-procedural oral corticosteroids to prevent in-segment restenosis after percutaneous coronary intervention. International Journal of Cardiology, 216 . pp. 1-8. doi:10.1016/j.ijcard.2016.04.105 ISSN 0167-5273.
|
PDF
WRAP_sstars_pre-publication.pdf - Accepted Version - Requires a PDF viewer. Download (1257Kb) | Preview |
Official URL: http://dx.doi.org/10.1016/j.ijcard.2016.04.105
Abstract
Background
Stent design and technological modifications to allow for anti-proliferative drug elution influence restenosis rates following percutaneous coronary intervention (PCI). We aimed to investigate whether peri-procedural administration of corticosteroids or the use of thinner strut cobalt alloy stents would reduce rates of binary angiographic restenosis (BAR) after PCI.
Methods
This was a two centre, mixed single and double blinded, randomised controlled trial using a factorial design. We compared (a) the use of prednisolone to placebo, starting at least six hours pre-PCI and continued for 28 days post-PCI, and (b) cobalt chromium (CoCr) to stainless steel (SS) alloy stents, in patients admitted for PCI. The primary end-point was BAR at six months.
Results
315 patients (359 lesions) were randomly assigned to either placebo (n = 145) or prednisolone (n = 170) and SS (n = 160) or CoCr (n = 160). The majority (58%) presented with an ACS, 11% had diabetes and 287 (91%) completed angiographic follow up. BAR occurred in 26 cases in the placebo group (19.7%) versus 31 cases in the prednisolone group (20.0%) respectively, p = 1.00. For the comparison between SS and CoCr stents, BAR occurred in 32 patients (21.6%) versus 25 patients (18.0%) respectively, p = 0.46.
Conclusion
Our study showed that treating patients with a moderately high dose of prednisolone for 28 days following PCI with BMS did not reduce the incidence of BAR. In addition, we showed no significant reduction in 6 month restenosis rates with stents composed of CoCr alloy compared to SS.
Item Type: | Journal Article | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Subjects: | R Medicine > RD Surgery | ||||||||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School | ||||||||||
Library of Congress Subject Headings (LCSH): | Stents (Surgery), Coronary arteries -- Stenosis -- Relapse -- Prevention, Adrenocortical hormones | ||||||||||
Journal or Publication Title: | International Journal of Cardiology | ||||||||||
Publisher: | Elsevier Ireland Ltd. | ||||||||||
ISSN: | 0167-5273 | ||||||||||
Official Date: | 1 August 2016 | ||||||||||
Dates: |
|
||||||||||
Volume: | 216 | ||||||||||
Page Range: | pp. 1-8 | ||||||||||
DOI: | 10.1016/j.ijcard.2016.04.105 | ||||||||||
Status: | Peer Reviewed | ||||||||||
Publication Status: | Published | ||||||||||
Access rights to Published version: | Restricted or Subscription Access | ||||||||||
Date of first compliant deposit: | 18 July 2016 | ||||||||||
Date of first compliant Open Access: | 15 April 2017 | ||||||||||
Funder: | National Institute for Health Research (Great Britain) (NIHR), Abbott Vascular (Firm), Cordis Corporation |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |
Downloads
Downloads per month over past year